The prospect of gene therapy for prostate cancer

Update on theory and status

Kenneth S. Koeneman, Jer Tsong Hsieh

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Molecularly based novel therapeutic agents are needed to address the problem of locally recurrent, or metastatic, advanced hormone-refractory prostate cancer. Recent basic science advances in mechanisms of gene expression, vector delivery, and targeting have rendered clinically relevant gene therapy to the prostatic fossa and distant sites feasible in the near future. Current research and clinical investigative efforts involving methods for more effective vector delivery and targeting, with enhanced gene expression to selected (specific) sites, are reviewed. These areas of research involve tissue-specific promoters, transgene exploration, vector design and delivery, and selective vector targeting. The 'vectorology' involved mainly addresses selective tissue homing with ligands, mechanisms of innate immune system evasion for durable transgene expression, and the possibility of repeat administration.

Original languageEnglish (US)
Pages (from-to)489-494
Number of pages6
JournalCurrent Opinion in Urology
Volume11
Issue number5
DOIs
StatePublished - 2001

Fingerprint

Transgenes
Genetic Therapy
Prostatic Neoplasms
Immune Evasion
Gene Expression
Research
Immune System
Hormones
Ligands
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

The prospect of gene therapy for prostate cancer : Update on theory and status. / Koeneman, Kenneth S.; Hsieh, Jer Tsong.

In: Current Opinion in Urology, Vol. 11, No. 5, 2001, p. 489-494.

Research output: Contribution to journalArticle

@article{373db3a6ef254e249a6ef7721fa61dc2,
title = "The prospect of gene therapy for prostate cancer: Update on theory and status",
abstract = "Molecularly based novel therapeutic agents are needed to address the problem of locally recurrent, or metastatic, advanced hormone-refractory prostate cancer. Recent basic science advances in mechanisms of gene expression, vector delivery, and targeting have rendered clinically relevant gene therapy to the prostatic fossa and distant sites feasible in the near future. Current research and clinical investigative efforts involving methods for more effective vector delivery and targeting, with enhanced gene expression to selected (specific) sites, are reviewed. These areas of research involve tissue-specific promoters, transgene exploration, vector design and delivery, and selective vector targeting. The 'vectorology' involved mainly addresses selective tissue homing with ligands, mechanisms of innate immune system evasion for durable transgene expression, and the possibility of repeat administration.",
author = "Koeneman, {Kenneth S.} and Hsieh, {Jer Tsong}",
year = "2001",
doi = "10.1097/00042307-200109000-00007",
language = "English (US)",
volume = "11",
pages = "489--494",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The prospect of gene therapy for prostate cancer

T2 - Update on theory and status

AU - Koeneman, Kenneth S.

AU - Hsieh, Jer Tsong

PY - 2001

Y1 - 2001

N2 - Molecularly based novel therapeutic agents are needed to address the problem of locally recurrent, or metastatic, advanced hormone-refractory prostate cancer. Recent basic science advances in mechanisms of gene expression, vector delivery, and targeting have rendered clinically relevant gene therapy to the prostatic fossa and distant sites feasible in the near future. Current research and clinical investigative efforts involving methods for more effective vector delivery and targeting, with enhanced gene expression to selected (specific) sites, are reviewed. These areas of research involve tissue-specific promoters, transgene exploration, vector design and delivery, and selective vector targeting. The 'vectorology' involved mainly addresses selective tissue homing with ligands, mechanisms of innate immune system evasion for durable transgene expression, and the possibility of repeat administration.

AB - Molecularly based novel therapeutic agents are needed to address the problem of locally recurrent, or metastatic, advanced hormone-refractory prostate cancer. Recent basic science advances in mechanisms of gene expression, vector delivery, and targeting have rendered clinically relevant gene therapy to the prostatic fossa and distant sites feasible in the near future. Current research and clinical investigative efforts involving methods for more effective vector delivery and targeting, with enhanced gene expression to selected (specific) sites, are reviewed. These areas of research involve tissue-specific promoters, transgene exploration, vector design and delivery, and selective vector targeting. The 'vectorology' involved mainly addresses selective tissue homing with ligands, mechanisms of innate immune system evasion for durable transgene expression, and the possibility of repeat administration.

UR - http://www.scopus.com/inward/record.url?scp=0034866627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034866627&partnerID=8YFLogxK

U2 - 10.1097/00042307-200109000-00007

DO - 10.1097/00042307-200109000-00007

M3 - Article

VL - 11

SP - 489

EP - 494

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 5

ER -